| ￥5800 | |
| Z04642-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 17 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 18 kDa and 22-25 kDa under reduced (R) condition, 30 kDa and 32-40 kDa under Non reducing (N) condition based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized Human VEGF R1, His Tag at 2 μg/ml(100 μl/well) on the plate. Dose response curve for VEGF121[Biotin], His & Avi, Human, His Avi Tag with the EC50 of 36.6ng/ml determined by ELISA. »
VEGF121[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced (R) condition and Non reducing (N) condition. The purity is greater than 95%. »
| Target Background | Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. |
| Synonyms | VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
